• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.

作者信息

Schmid Sabine, Stewart Erin L, Martins-Filho Sebastiao N, Cabanero Michael, Wang Ao, Bao Hua, Wu Xue, Patel Deval, Chen Zhuo, Law Jennifer H, Bradbury Penelope A, Shepherd Frances A, Leighl Natasha, Tsao Ming-Sound, Pugh Trevor, Bratman Scott V, Sacher Adrian, Liu Geoffrey

机构信息

University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.

出版信息

Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.

DOI:
10.1016/j.cllc.2020.03.009
PMID:32389504
Abstract
摘要

相似文献

1
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.通过循环肿瘤DNA分析对接受奥希替尼治疗的表皮生长因子受体（EGFR）突变型肺腺癌患者的多种耐药机制进行早期检测
Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.
2
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.循环肿瘤 DNA 清除预测 EGFR 突变型肺癌患者对奥希替尼的临床反应。
Lung Cancer. 2020 May;143:67-72. doi: 10.1016/j.lungcan.2020.03.020. Epub 2020 Mar 19.
3
Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report.肺腺癌脑脊液中脑膜转移的检测：病例报告
Clin Lung Cancer. 2020 Sep;21(5):e493-e496. doi: 10.1016/j.cllc.2020.04.010. Epub 2020 Apr 15.
4
Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.奥希替尼治疗双EGFR L747S和G719C突变患者的临床疗效
J Thorac Oncol. 2019 Jul;14(7):e151-e153. doi: 10.1016/j.jtho.2019.02.034.
5
Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.晚期 EGFR 突变型肺腺癌患者血浆循环肿瘤 DNA 的体细胞拷贝数改变。
Biomolecules. 2021 Apr 21;11(5):618. doi: 10.3390/biom11050618.
6
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.利用下一代测序技术探索非小细胞肺癌患者二线奥希替尼的耐药机制及其预后意义。
Eur J Cancer. 2021 May;148:202-210. doi: 10.1016/j.ejca.2021.01.052. Epub 2021 Mar 18.
7
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.在考虑使用奥希替尼治疗的晚期非小细胞肺癌患者中，采用循环肿瘤 DNA 进行综合分析的作用。
Cancer Med. 2021 Jun;10(12):3873-3885. doi: 10.1002/cam4.3929. Epub 2021 May 12.
8
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。
J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.
9
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.通过血液活检确定对奥希替尼的耐药机制。
Clin Lung Cancer. 2019 Nov;20(6):e597-e600. doi: 10.1016/j.cllc.2019.08.002. Epub 2019 Aug 26.
10
Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.晚期肺腺癌患者重复活检检测 EGFR T790M 突变：奥希替尼的相关因素和治疗结果。
PLoS One. 2024 Sep 19;19(9):e0310079. doi: 10.1371/journal.pone.0310079. eCollection 2024.

引用本文的文献

1
Direct GDP-KRAS inhibitors and mechanisms of resistance: the tip of the iceberg.直接作用的GDP-KRAS抑制剂与耐药机制：冰山一角
Ther Adv Med Oncol. 2023 Mar 16;15:17588359231160141. doi: 10.1177/17588359231160141. eCollection 2023.
2
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?基于ctDNA/cfDNA的液体活检能否取代组织活检用于EGFR突变非小细胞肺癌的精准治疗？
J Clin Med. 2023 Feb 10;12(4):1438. doi: 10.3390/jcm12041438.
3
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
表皮生长因子受体（EGFR）突变的非小细胞肺癌治疗后发生小细胞肺癌转化
J Clin Med. 2022 Mar 5;11(5):1429. doi: 10.3390/jcm11051429.
4
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis.用于新发或转化型小细胞肺癌的液体活检：不同应用的系统评价和荟萃分析
Cancers (Basel). 2021 May 8;13(9):2265. doi: 10.3390/cancers13092265.